Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Glaukos Corp (NY: GKOS ) 127.43 +2.27 (+1.81%) Official Closing Price Updated: 7:00 PM EDT, Aug 16, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Glaukos Corp < Previous 1 2 3 4 5 6 7 8 Next > Glaukos Achieves Pipeline Milestone with Enrollment Completion in Phase 3 Confirmatory Trial for Epioxa (Epi-on) June 05, 2023 From Glaukos Corporation Via Business Wire Glaukos Announces Participation in the William Blair Growth Stock Conference May 24, 2023 From Glaukos Corporation Via Business Wire Tyson Foods, PayPal And 3 Stocks To Watch Heading Into Monday May 08, 2023 With US stock futures trading slightly lower this morning on Monday, some of the stocks that may grab investor focus today are as follows: Via Benzinga Glaukos Announces FDA Acceptance of NDA Submission for iDose TR May 05, 2023 From Glaukos Corporation Via Business Wire Glaukos: Q1 Earnings Insights May 03, 2023 Via Benzinga Expert Ratings for Glaukos April 18, 2023 Via Benzinga Earnings Preview For Glaukos February 21, 2023 Via Benzinga Analyst Expectations for Glaukos's Future December 28, 2022 Via Benzinga Glaukos Announces First Quarter 2023 Financial Results May 03, 2023 From Glaukos Corporation Via Business Wire Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2023 American Society of Cataract and Refractive Surgery Annual Meeting May 01, 2023 From Glaukos Corporation Via Business Wire Glaukos Announces the Release of its 2022 Sustainability Report April 19, 2023 From Glaukos Corporation Via Business Wire Glaukos to Release First Quarter 2023 Financial Results after Market Close on May 3 April 12, 2023 From Glaukos Corporation Via Business Wire 10 Analysts Have This to Say About Glaukos December 28, 2022 Via Benzinga What 10 Analyst Ratings Have To Say About Glaukos December 28, 2022 Via Benzinga Glaucoma Is The Second Leading Cause Of Blindness Globally – Skye Bioscience Appears To Be Making Rapid Progress In The Development Of Their Candidate To Treat It March 09, 2023 Biomed company Skye Bioscience (OTCQB: SKYE) has seen positive results in its clinical research so far and is preparing for the next stage in the development of its therapy for eye disease. Via Benzinga Glaukos Submits New Drug Application to U.S. FDA for iDose TR February 27, 2023 From Glaukos Corporation Via Business Wire NVIDIA To Rally Over 20%? Here Are 10 Other Analyst Forecasts For Thursday February 23, 2023 Goldman Sachs boosted the price target for Vir Biotechnology, Inc. (NASDAQ: VIR) from $41 to $53. Goldman Sachs analyst Paul Choi maintained a Buy rating on the stock. Vir Biotechnology shares rose... Via Benzinga Glaukos Announces Fourth Quarter and Full Year 2022 Financial Results February 22, 2023 From Glaukos Corporation Via Business Wire 7 Analysts Have This to Say About Glaukos December 12, 2022 Via Benzinga Analyst Ratings for Glaukos December 12, 2022 Via Benzinga Glaukos Announces Participation in the Citi Healthcare Conference February 15, 2023 From Glaukos Corporation Via Business Wire Glaukos to Release Fourth Quarter and Full Year 2022 Financial Results after Market Close on February 22 February 01, 2023 From Glaukos Corporation Via Business Wire Glaukos Announces Positive Results for iDose TR Exchange Trial, Highlighting Favorable Safety and Tolerability January 10, 2023 From Glaukos Corporation Via Business Wire Glaukos Announces Positive Clinical Updates for Several Corneal Health Pipeline Programs January 10, 2023 From Glaukos Corporation Via Business Wire Glaukos Announces Participation in the J.P. Morgan Healthcare Conference December 28, 2022 From Glaukos Corporation Via Business Wire Benzinga's Top Ratings Upgrades, Downgrades For December 22, 2022 December 22, 2022 Via Benzinga Skye Bioscience (OTCQB: SKYE) Heads Into 2023 As A Clinical-Stage Company After Dosing Its First Human Participants December 22, 2022 This year has been quite busy for Skye Bioscience Inc. (OTCQB: SKYE). Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For December 19, 2022 December 19, 2022 Via Benzinga Moderna To Rally Over 42%? Here Are 10 Other Price Target Changes For Monday December 19, 2022 Morgan Stanley cut VTEX (NYSE: VTEX) price target from $7 to $5. Morgan Stanley analyst Cesar Medina downgraded the stock from Overweight to Equal-Weight. VTEX shares fell 4.9% to close at $3.52 on... Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For December 12, 2022 December 12, 2022 Via Benzinga < Previous 1 2 3 4 5 6 7 8 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.